CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...

and continue to experiment with the extended use of therapeutics originally developed to treat the COVID-19 infection, which show mixed results. Additionally, the Centers for Disease Control and ...

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Among adults in Ravensburg, Germany, financial incentives for COVID-19 vaccination did not result in significant changes to vaccine uptake and may have inadvertently lowered community vaccination ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

The rate of antiviral prescriptions was 67% lower in pregnant than in nonpregnant women, including those with one or more high-risk underlying conditions.

The CIA now believes the virus responsible for the COVID-19 pandemic most likely originated from a laboratory, according to an assessment released Saturday that points the finger at China even ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...